

ARIZONA
HEALTH CARE COST
CONTAINMENT SYSTEM

REINSURANCE **HOT NEWS**

May 28TH, 2026

AHCCCS is pleased to announce the addition 6 of the following drugs to the High-Cost Specialty Drug Reinsurance (BIO) effective:

Effective April 1, 2026:

Aqvesme - (Mitapivat)-Indicated for the treatment of anemia in adults with alpha- or beta-thalassemia

Berinert-(C-1 Esterase Inhibitor)-Indicated for the treatment of acute abdominal, facial, or laryngeal hereditary angioedema (HAE) attacks in adult and pediatric patients

Ctexli - (Chenodiol) - A bile acid indicated for treatment of cerebrotendinous xanthomatosis(CTX) in adults

Korlym-(Mifepristone)- Indicated to control high blood sugar (hyperglycemia) secondary to hypercortisolism in adult patients with endogenous Cushing syndrome who have type 2 diabetes mellitus or glucose intolerance and who cannot have surgery or whom surgery has failed

Alyftrek- (Vanzacaftor, Tezacaftor, Deutivicaftor)- Indicated for the treatment of cystic fibrosis (CF) in adult and pediatric patients aged 6 years and older who have a clinical diagnosis of CF and who have at least one variant in the CFTR gene that is either responsive based on clinical and/or in vitro data results in production of CFTR protein. In addition, the gene mutation that is responsive to Alyftrek is not responsive to Trikafta

Effective October 1,2026:

Kygevvi- (Doxecitine & Doxribtimine)-Indicated for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years of age.

Beqvez-(**Discontinued**)- Indicated for the treatment of adults with moderate to severe hemophilia B

[Reminder from the Reinsurance Manual \(Page 20\)](#)

"For multiple reinsurance drugs to treat the same medical condition, please refer to the AHCCCS Fee For Service prior authorization criteria to determine if the criterion supports the use of multiple medications given/administered at the same time to an individual. When the prior authorization criterion is not supportive of the use of multiple drugs to treat the same condition, the reinsurance program will not reimburse multiple medications. For additional

questions, please check with the Medical Management staff assigned to the MCO. "

Here is the Link to the Updated High-Cost Specialty Drug List:
<https://www.azahcccs.gov/PlansProviders/Downloads/Reinsurance/BiologicandHighCostSpecialtyDrugList.xlsx>